Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OKI-219,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OnKure Announces Preliminary Safety Data from PIKture-01 Trial of OKI-219
Details : OKI-219 is a PI3K alpha H1047R inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with solid tumors.
Product Name : OKI-219
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : OKI-219,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OKI-219,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leerink Partners
Deal Size : $65.0 million
Deal Type : Private Placement
OnKure Closes Merger with Reneo Pharmaceuticals, Raises $65 Million
Details : The combined company will focus on OnKure’s candidates targeting oncogenic mutations in PI3K alpha, including OKI-219, which is in Phase 1 for the treatment of solid tumors.
Product Name : OKI-219
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 10, 2024
Lead Product(s) : OKI-219,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leerink Partners
Deal Size : $65.0 million
Deal Type : Private Placement
Lead Product(s) : OKI-219
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OnKure Announces IND Clearance by FDA Enabling Phase 1 Initiation for OKI-219
Details : OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3Kα H1047R, which is being evaluated for the treatment of HER2+/ PI3Kα H1047R breast cancer.
Product Name : OKI-219
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : OKI-219
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OKI-219
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Surveyor Capital
Deal Size : $54.0 million
Deal Type : Series C Financing
OnKure Therapeutics Announces $54 Million Series C Financing
Details : The proceeds will be used to support the continued development of OnKure’s differentiated pipeline of next generation precision medicines, including the advancement of its lead discovery program OKI-219, a selective PI3K alpha H1047R inhibitor, into th...
Product Name : OKI-219
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : OKI-219
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Surveyor Capital
Deal Size : $54.0 million
Deal Type : Series C Financing
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OKI-179 combined with binimetinib in NRAS-mutated melanoma or combined with binimetinib + encorafenib in BRAF-mutated colorectal xenografts showed significantly increased regressions compared to either single agent following two weeks of dosing.
Product Name : OKI-179
Product Type : Peptide
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : University of Colorado
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OKI-179, a novel oral Class I histone deacetylase inhibitor for treatment of wide range of solid and hematological malignancies, increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma.
Product Name : OKI-179
Product Type : Peptide
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : University of Colorado
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OKI-179 is a novel, oral Class I histone deacetylase (HDAC) inhibitor for the potential treatment of a wide range of solid and hematological malignancies.
Product Name : OKI-179
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : OKI-179,Binimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable